Clinical harm from failure to deploy personalized medicine for patients with metastatic non–small cell lung cancer

Journal of Managed Care and Specialty Pharmacy · Published 2026-07-27 · DOI 10.18553/jmcp.2026.32.8.1029

Free full text

Authors (9)

Kristen Migliaccio-Walle, Scott J. Spencer, David L. Veenstra, Robert H. Dumanois, Jason S. White, Lucy Langer, Daryl Pritchard, John Fox, Scott D. Ramsey

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Migliaccio-Walle, K., Spencer, S., Veenstra, D., et al. (2026). Clinical harm from failure to deploy personalized medicine for patients with metastatic non–small cell lung cancer. Journal of Managed Care and Specialty Pharmacy. https://doi.org/10.18553/jmcp.2026.32.8.1029

Related articles

• Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology · Oncology and Therapy · 2026 · Cites or is cited by this article
• Do Targeted NGS Panels Include NSCLC Guideline-Recommended Biomarkers? · American Journal of Managed Care · 2026 · Cites or is cited by this article
• Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Patient experience data in formulary decision-making: Payer-reported perceptions and use · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal
• Evaluating the design and implementation challenges of the Centers for Medicare & Medicaid Services’ Cell and Gene Therapy Access Model · Journal of Managed Care and Specialty Pharmacy · 2026 · Same journal